Wall Street brokerages expect Aurora Cannabis Inc (NYSE:ACB) to report earnings per share of ($0.03) for the current quarter, according to Zacks. Six analysts have issued estimates for Aurora Cannabis’ earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.05). Aurora Cannabis reported earnings per share of $0.09 in the same quarter last year, which would suggest a negative year over year growth rate of 133.3%. The company is scheduled to issue its next earnings report on Monday, November 11th.
On average, analysts expect that Aurora Cannabis will report full year earnings of ($0.10) per share for the current financial year, with EPS estimates ranging from ($0.16) to ($0.02). For the next financial year, analysts expect that the firm will report earnings of ($0.02) per share, with EPS estimates ranging from ($0.15) to $0.05. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Aurora Cannabis.
ACB has been the topic of several research reports. CIBC started coverage on Aurora Cannabis in a research note on Tuesday, September 24th. They set a “neutral” rating and a $7.00 price target on the stock. ValuEngine raised Aurora Cannabis from a “hold” rating to a “buy” rating in a research note on Wednesday, August 21st. Zacks Investment Research raised Aurora Cannabis from a “sell” rating to a “hold” rating in a research note on Thursday, September 12th. Pi Financial set a $7.00 target price on Aurora Cannabis and gave the company a “buy” rating in a research note on Tuesday, October 15th. Finally, Compass Point set a $8.00 target price on Aurora Cannabis and gave the company a “hold” rating in a research note on Thursday, September 12th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $7.84.
Shares of ACB traded up $0.01 during trading hours on Monday, hitting $3.69. 14,682,249 shares of the stock traded hands, compared to its average volume of 19,920,086. The company has a current ratio of 1.52, a quick ratio of 1.14 and a debt-to-equity ratio of 0.09. Aurora Cannabis has a 1-year low of $3.40 and a 1-year high of $10.32. The firm has a market capitalization of $3.80 billion, a PE ratio of -16.77 and a beta of 2.39. The business has a fifty day moving average of $4.79 and a 200-day moving average of $6.89.
A number of large investors have recently added to or reduced their stakes in ACB. Amundi Pioneer Asset Management Inc. acquired a new position in Aurora Cannabis in the first quarter valued at about $768,000. Calton & Associates Inc. raised its position in shares of Aurora Cannabis by 11.0% during the second quarter. Calton & Associates Inc. now owns 18,225 shares of the company’s stock worth $143,000 after purchasing an additional 1,800 shares during the period. Valeo Financial Advisors LLC raised its position in shares of Aurora Cannabis by 156.2% during the second quarter. Valeo Financial Advisors LLC now owns 6,561 shares of the company’s stock worth $51,000 after purchasing an additional 4,000 shares during the period. Exane Derivatives raised its position in shares of Aurora Cannabis by 575.2% during the second quarter. Exane Derivatives now owns 31,006 shares of the company’s stock worth $242,000 after purchasing an additional 26,414 shares during the period. Finally, North Star Investment Management Corp. raised its position in shares of Aurora Cannabis by 22.4% during the second quarter. North Star Investment Management Corp. now owns 17,500 shares of the company’s stock worth $137,000 after purchasing an additional 3,200 shares during the period. 8.80% of the stock is currently owned by hedge funds and other institutional investors.
Aurora Cannabis Company Profile
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Featured Article: Cost of Goods Sold (COGS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.